



**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

**PCT/EP 03 / 136 01**

**RECEIVED**

**27 FEB 2004**

**WIPO**

**PCT**

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

**Patentanmeldung Nr. Patent application No. Demande de brevet n°**

**02447241.7**

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**R C van Dijk**

**BEST AVAILABLE COPY**



Anmeldung Nr:  
Application no.: 02447241.7  
Demande no:

Anmeldetag:  
Date of filing: 04.12.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

PamGene B.V.  
Burgemeester Loeffplein 70a  
5211 RX Den Bosch  
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

Novel method for probe hybridisation of immobilized genomic DNA

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

G12Q1/68

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL  
PT SE SI SK TR

## NOVEL METHOD FOR PROBE HYBRIDISATION OF IMMOBILIZED GENOMIC DNA

### Field of the Invention

5 The present invention relates to methods for undigested genomic nucleic acid material hybridisations and detection and quantification of target nucleic acids in a genomic DNA sample.

The present invention relates in particular to methods for automated multiple amplifiable probe hybridisations onto genomic DNA.

10 The methods of the present invention are particularly useful in screening methods for detection of copy number and changes in copy number of genomic DNA.

### Background of the Invention

Abnormalities of DNA copy number account for many genetic diseases in living  
15 organisms, including many human genetic disorders. The largest of these abnormalities involve changes in copy number in entire chromosomes; for example in monosomies and trisomies (for example trisomy 21 resulting in Down syndrome), and segmental abnormalities such as 5p deletion in cri-du-chat syndrome. Alternatively, genetic diseases such as for example *DMD* (Duchenne muscular dystrophy), *BRCA1*  
20 (breast cancer) or *MSH2/MLH1* (hereditary nonpolyposis colorectal cancer or HNPCC) may evolve from smaller copy number changes in genomic DNA which are too small to be detected by conventional cytogenetics. Further, at the level of individual genes, specific inherited diseases can result from deletions or duplications involving individual exons or entire genes.

25

The detection of changes in copy number in a complex genome is not straightforward. Commonly applied methods for diagnosing genetic diseases due to copy number alterations involve for example quantitative multiple PCR, Southern blotting and comparative genomic hybridisation. These techniques, however, albeit  
30 commonly practiced and to a great extent recognized for their reliability are subject to a number of disadvantages. Southern blotting is time consuming and duplications may be difficult to be detected. A disadvantage of multiplex PCR for example is its restriction to the number of loci which can be analysed simultaneously. Although comparative genomic hybridisation can analyse a whole genome in a single test,  
35 resolutions were proven to be relatively low. It is clear from the above that detection of copy number in a complex genome has a great technical challenge.

Despite its fundamental importance, it is only recently that systematic approaches have been developed to assess copy number at specific genetic loci, or to examine genomic DNA for sub-microscopic deletions of unknown location. New approaches include for example multiplex amplifiable probe hybridisation as described in WO 00/53804 (Armour). Although the power and specificity of multiplex amplifiable probe hybridisation is proven by the simultaneous assessment of copy number at large sets of human loci, this technique suffers from the general disadvantage that in particular the handling step with regard to removal of unbound probes is quite time-consuming.

Due to the exponential growth of research activity and diagnostic development, demand for improved hybridisation procedures is imperative and those skilled in the art recognize that it would be a distinct advantage in diagnostic research and extremely beneficial in commercial diagnostics if a highly efficient and economic diagnostic tool would be available.

Although flow-through hybridisation methods known in the art have become appreciated over the last years for their efficiency in performing numerous analysis technologies, such methods are restricted to the hybridisation of probes to four types of nucleic acid probes: large sections of DNA, small DNA (including cDNA), RNA, and peptide nucleic acids.

The present invention describes the principle of a unique flow-through hybridisation process for immobilized undigested genomic DNA and a device for the said purpose whereby the hybridisation time as well as the amount of reagents used for hybridisation can be reduced by many folds.

The present invention aims at providing improved methods for the quantitative detection of nucleic acids in a genomic sample with high resolution.

It is a further object of the present invention to provide methods for the quantitative detection of nucleic acids in a genomic sample with a much improved sensitivity level.

It is a further object of the present invention to provide methods for the quantitative detection of nucleic acids in a sample possessing an improved time-management.

It is a further object to provide devices, apparatuses and kits for carrying out said methods.

### **Summary of the Invention**

5 In order to accurately quantify nucleic acids within a genomic nucleic acids sample, the present invention provides a method for hybridisation of probes onto immobilized genomic DNA comprising the steps of (a) providing genomic DNA and denaturing said genomic DNA; (b) immobilizing said denatured genomic DNA onto a matrix; (c) providing a set of probes and passing said probes through said matrix under  
10 conditions favouring hybridisation of the probes to its complementary sequence in said genomic DNA; and (d) washing off non-hybridised probes through said matrix, leaving formed hybridised genomic DNA/probe complexes for further analysis.

The present invention provides methods for flow-through genomic hybridisation  
15 which are fast (high-speed), highly sensitive, highly specific and miniaturized.

A general outline of the hybridisation methods provided by the present invention is given in Figure 1.

### **Detailed Description of the Invention**

Before the present method and solutions used in the method are described, it is to be understood that this invention is not limited to particular methods, components, or solutions described, as such methods, components, and solutions may, of course, vary.

25 In the present specification and the appended claims, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise.

It should also be understood that the terminology used herein is not intended to be  
30 limiting, since the scope of the present invention will be limited only by the appended claims.

Accordingly, definitions should not be understood to limit the scope of the invention. Rather, they should be used to interpret the language of the description and, where appropriate, the language of the claims. These terms may also be understood more  
35 fully in the context of the description of the invention. If a term is included in the description or the claims that is not further defined within the present description, or

that cannot be interpreted based on its context, then it should be construed to have the same meaning as it is understood by those skilled in the art.

The present invention relates in particular to screening for sequence copy number and to screening for changes in copy number of a plurality of nucleic acid sequences  
5 In a genome or genomic sample.

The terms "genome", "genomic content", "genomic sample", "genomic DNA", "genomic nucleic acid material" and "genetic material" are used interchangeably throughout the present specification and mean the nucleic acid molecules in an  
10 organism or cell that are the ultimate source of heritable genetic information of the organism. For most organisms, a genome consists primarily of chromosomal DNA, but it can also include plasmids, mitochondrial DNA, and so on. For some organisms, such as RNA viruses, a genome consists of RNA. As used within the present specification, genomic DNA is undigested unless otherwise stated.

15

By "nucleic acid" is meant DNA, RNA, or other related compositions of matter that may include substitution of similar moieties. For example, nucleic acids may include bases that are not found in DNA or RNA, including, but not limited to, xanthine, inosine, uracil in DNA, thymine in RNA, hypoxanthine, and so on. Nucleic acids may  
20 also include chemical modifications of phosphate or sugar moieties, which can be introduced to improve stability, resistance to enzymatic degradation, or some other useful property.

The loss or reduction in the normal number of copies of a genetic sequence  
25 (deletion) or the increase in copy number (amplification) are of widespread general importance. Such genetic alterations are known to underlie phenotype characteristics both somatic and germline. The demonstration of the site and nature of such genetic alteration is critical in the identification of the genes responsible and to the development of appropriate and effective treatments and therapies.

30

The present invention provides for methods to obtain genetic information from samples containing or suspected to have genomic content. It is medically and/or environmentally and/or socially important to identify genomic disorders. It will be well appreciated that also e.g. infectious organisms may be identified and quantified in  
35 such samples for optimal treatment of infections or contamination and for maintaining public health.

Methods according to the present invention are particularly designed for probe hybridisation onto immobilized genomic nucleic acid material. Hybridisation methods according to the present invention are characterized in that undigested genomic contents can be immobilized and subjected to flow-through probe hybridisation techniques.

Accordingly, in one embodiment of the present invention, a hybridisation method is provided wherein the genomic DNA is undigested genomic DNA.

Another object of the invention is to provide for the use of a method according to the present specification and as described herein for genomic DNA hybridisation.

The immobilized genetic material within the present invention originates from a sample to be analysed for the presence/absence of any genomic abnormality.

By the term "genomic abnormality" is meant any deviation from a normal genomic content status. A genomic content status characterizes the condition or part thereof of a sample or the corresponding whole from which said genomic content was identified and quantified. A genomic abnormality may prevail through for example mutation(s) at the level of entire chromosomes including deletions and duplications, segmental abnormalities, genomic DNA deletions and duplications at the level of individual genes, involving individual exons or entire genes.

Abnormalities or irregularities involving endogenes as well as exogenes may lead to genomic abnormalities.

Accordingly, a genomic abnormality may equally prevail through the presence of exogenous nucleic acids such as by way of example and not limitation: naked autonomous replicating nucleic acids including for example plasmids and viroids; and embodied autonomous replicating nucleic acids such as pathogens, parasites, and contaminants. Said pathogen, parasite, and contaminant may be algae, archaea, bacteria; viruses; fungi including yeasts, molds and mycorrhizae; nematodes; protozoa and microsporidiae.

A sample containing or suspected to have a genomic content may be biological material or any material comprising biological material from which nucleic acids may be prepared and analysed for the qualitative and quantitative presence of particular nucleic acid sequences. Genomic nucleic acid material to be used in the methods of the present invention may be within its sample format for direct analysis. However, a

particular useful format is provided when the sample is subjected to some preparation prior to use in the analysis of the present invention. Said preparation may involve the removal of non-nucleic acid debris and suspension/dilution of the pure or isolated nucleic acid material in water or an appropriate buffer.

5

The genomic material may be isolated from virtually any sample. However, usually, the sample is a biological or a biochemical sample. The term "biological sample," as used herein, refers to a sample obtained from an organism or from components (e.g., cells) of an organism. The sample may be of any biological tissue or fluid. Frequently  
10 the sample will be a "clinical sample" which is a sample derived from a patient. Such samples include, but are not limited to, sputum, cerebrospinal fluid, blood, blood fractions such as serum including foetal serum (e.g., SFC) and plasma, blood cells (e.g., white cells), tissue or fine needle biopsy samples, urine, peritoneal fluid, and pleural fluid, or cells there from. Biological samples may also include sections of  
15 tissues.

Accordingly, in one embodiment of the present invention, a hybridisation method is provided, wherein the genomic DNA is isolated. Methods for genomic DNA isolation from various samples are well known in the art.

20

Typically, genomic DNA is denatured prior to immobilization. DNA may be denatured by boiling or other methods as well known in the art.

The denatured DNA is subsequently immobilized within a matrix.

25 The term "matrix" refers to a material in which genetic material may be enclosed or embedded (as for study). The term matrix encompasses a wide range of potential substrates that can be used for the immobilization of genomic DNA.

Generally, the matrix can be composed of any material which will permit immobilization of undigested genomic DNA or nucleic acids and which will not melt or  
30 otherwise substantially degrade under the conditions used to immobilize said genomic material and which allows hybridisation of said immobilized genomic material with probes by flow-through hybridisation.

A number of materials suitable for use as matrices in the present invention have been described in the art. Materials particularly suitable for use as matrices in the  
35 present invention include any type of permeable synthetic materials or natural materials provided that the pore diameter in case of a porous matrix or the mesh size in case of a matrix network allow for the permeation of the undigested genomic



nucleic acid material. Particular suitable matrix materials have pore sizes comprised within a range of 0.6  $\mu\text{m}$  to 2  $\mu\text{m}$  including the outer limits. It will be well appreciated by a person skilled in the art that matrix thickness may vary in function of matrix strength, i.e. the thinner a matrix may be; the stronger the material is, wherein thin material might still support flow-through hybridisation and/or flow-through of reaction components. A particular suitable matrix is a thin pore matrix. Advantages, among others, of such particular suitable matrix is the limited amount of genomic DNA material needed. A particular suitable matrix thickness is within a range of 0.1 mm to 1 mm, including the outer limits. A more particular suitable matrix thickness is within a range of 0.3 mm to 0.5 mm including the outer limits.

It will be well appreciated that a combination of matrix materials may be envisaged in obtaining a desired matrix format characterized by a desired pore size(s) and strength.

Accordingly, in one embodiment of the present invention, a hybridisation method is provided, wherein said denatured genomic DNA is permeated within said matrix.

A matrix may be in the form of sheets, films or membranes and are permeable. For example, a matrix may consist of fibres such as glass wool or other glass or synthetic fibres such as plastic fibres, polyamide fibres (e.g. nylon) and the like. A matrix may equally consist of animal fibres such as silk and wool, or plant or vegetable fibres such as cotton, cellulose fibres and nitrocellulose fibres or cellulosic fibres including for example acetate and triacetate.

The matrix may be planar or have a simple or a complex shape. Particular useful matrices are membranes comprising a 3D network structure of which the surface to which the genomic nucleic acids are adhered is external surface as well as internal surface of the matrix. However, as will be appreciated in the art, it will be predominantly the internal surfaces that will have adhered thereto the genomic DNA.

Accordingly, in one embodiment of the present invention, a hybridisation method is provided, wherein the matrix is a membrane.

In a further embodiment of the present invention, a hybridisation method is provided, wherein said membrane comprises a 3D network structure.

In yet a further embodiment of the present invention, a hybridisation method is provided, wherein said network structure is a fibre network structure.

5 In yet a further embodiment of the present invention, a hybridisation method is provided, wherein said fibre is of vegetable origin.

In yet a further embodiment of the present invention, a hybridisation method provided, wherein said fibre is cellulose.

10 The principle of the present invention is using a flow-through mechanism by which the probes pass through the membrane structure, allowing these probes coming in close contact with the corresponding complementary sequences within the immobilized genomic nucleic acids so that the target sequences can be effectively detected in high sensitivity and specificity.

15 Accordingly, in one embodiment of the present invention, a hybridisation method is provided, wherein said network structure is a flow-through structure.

20 Whatever the substrate or matrix material, there are a number of ways that nucleic acids can be attached or immobilized. Most common are physical adsorptive processes or chemical linking processes, including ultraviolet (UV) or covalent methods.

25 A great deal of interest has been shown in the production of activated membranes, that is, membranes that have direct reaction chemistry available on their surfaces. The ability to apply an aqueous sample directly to the membrane, and to have binding occur naturally without the need for further reagents, offers significant advantages, these are especially known with respect to the production of microarrays. Several different activation chemistries are well known in the art.

30 Accordingly, in one embodiment of the present invention, a hybridisation method is provided, wherein the matrix is activated with an affinity conjugate.

35 In a further embodiment, a hybridisation method is provided, wherein said affinity conjugate is chosen from the group comprising poly-L-lysine, poly-D-lysine, 3-aminopropyl-triethoxysilane, poly-arginine, polyethyleneimine, polyvinylamine,

polyallylamine, tetraethylenepentamine, ethylenediamine, diethylenetriamine, triethylenetetramine, pentaethylenehexamine and hexamethylenediamine.

5 In yet a further embodiment, a hybridisation method is provided, wherein said affinity conjugate is poly-L-lysine.

Handling of the matrix is greatly improved by means of a device for holding said matrix such as described in PCT/EP02/02446 which is herewith incorporated by reference.

10

High-throughput analysis of numerous samples simultaneously may be accommodated by a system such as described in European Application No. 02076728.1, herewith incorporated by reference, which discloses a system for conducting bioassays, comprising a substrate plate with a number of wells, and an incubation device for holding the plate. This known analytical test device is composed of a plastic support wherein openings in the plastic support define wells with a certain diameter, said wells being open at the top for sample or probe application and having a substrate defining the bottom of each well. Said substrate may be a matrix as described in the present specification.

20

A system as described above allows for parallel processing of a large number of genomic nucleic acid samples and may be applied in automated robotic platforms. Such system usually comprises a microplate with an array of wells arranged in rows and columns, wherein the bottom of each well is a matrix having a flow-through fibre network. Using for example a microplate with an array of ninety-six wells allows a parallel processing of a large number of hybridisations resulting in a very efficient high-throughput analysis.

25

Accordingly, it is an object of the present invention to provide a device for flow-through hybridisation of probes onto immobilized genomic DNA comprising a well holder, said well holder comprising one or more round wells with a fixed diameter, said wells exposing a fibre network matrix; wherein said matrix permits immobilization of undigested genomic DNA and which allows hybridisation of said immobilized genomic material with probes by flow-through hybridisation.

30  
35

In one embodiment of the present invention, a device for flow-through hybridisation of probes onto immobilized genomic DNA is provided wherein said matrix permits permeation of undigested genomic DNA.

- 5 Application of a pressure difference over the matrix will force the probes through the matrix 3D network structure, thereby creating a low pressure within the wells. By removing said low pressure, the probes are automatically forced back through the network of the matrix. Higher pressures will create a more rapid flow of the probes through the matrix structure. By alternately creating a low pressure over the matrix  
10 and removing the low pressure, the probes are forced through the matrix network a number of times.

Accordingly, it is another object of the present invention to provide an apparatus for flow-through hybridisation of probes onto immobilized genomic DNA comprising:

- 15 (a) a device for flow-through hybridisation of probes onto immobilized genomic DNA comprising a well holder, said well holder comprising one or more round wells with a fixed diameter, said wells exposing a fibre network matrix;  
(b) means for addition of a controlled amount of fluid to at least one of the wells  
20 of the device as described in (a);  
(c) means for applying and/or maintaining a controlled pressure difference over the matrix in each of the wells.

An optimum flow-rate is such that the residence time of the probe molecules near the  
25 immobilized target sequences is sufficient to generate hybridisation events in the shortest possible time.

Hybridisations are usually performed with flow rates comprised between 50mm/30min and 250mm/30min including the outer limits. Particular suitable flow rates are comprised between 75mm/30min and 200mm/30min including the outer  
30 limits. More particular suitable flow rates are comprised between 100mm/30min and 150mm/30min including the outer limits. Usually, a particular suitable flow rate is 130mm/30min including the outer limits.

Accordingly, in one embodiment of the present invention, hybridisation methods are  
35 provided, wherein the matrix allows for a flow rate comprised between 50mm/30min and 250mm/30min including the outer limits.

A flow-through incubation, as employed in the methods as described herein, gives significantly reduced hybridisation times. Positive or negative pressure may be applied to the matrix in order to pump the probe solution dynamically up and down through the matrix pores or matrix network which may enhance the diffusion of the probes to the target sequences within the immobilized genomic material.

The duration of one cycle of forward and backward flow of probe solution across the matrix membrane may be comprised between 10 min and 1 sec. Usually, duration of one cycle is comprised between 5 min and 10 sec. More usually, duration of one cycle is comprised between 5 min and 10 sec. Yet more usually, duration of one cycle is comprised between 1 min and 45 sec. A particular suitable example of duration of a single cycle of forward and backward flow is 30 sec.

In another embodiment of the present invention, a hybridisation method is provided, wherein said probes are passed through said matrix by at least one cycle of alternating downwards and upwards flow.

It is common to perform analysis at a single constant temperature; the preferred temperature will depend on the envisaged hybridisation stringency. Adjustment of the hybridisation temperature may be accomplished by coupling of the matrix via a holding device to a heating device such as a water bath or a conductive heating plate. Alternatively, an incubator system with a temperature control system may be provided wherein said holding device comprising one or more matrices may be housed. Such incubator system is described in for example PCT/EP02/02448 which is hereby incorporated by reference.

Once sufficient time has elapsed or sufficient flow cycles have elapsed to provide for hybridisation, unbound probes are washed thoroughly away by means of a post-hybridisation flow-through wash step. A dynamical pumping allows immediate and highly efficient removal of any unbound probe in as little as one single downward flow. In general, flow conditions with regard to number of cycles and flow speed may be varied according to the envisaged stringency.

In one embodiment of the present invention, a hybridisation method is provided, wherein the washing step is carried out by passing through the matrix a wash fluid by at least one cycle of downwards flow.

Any bound probe is subsequently recovered and amplified. Said recovering and amplification may be essentially simultaneously, i.e. the probe-recovering step may be performed in a nucleic acid amplification environment. For example, nucleic acids immobilized onto a membrane and bound to identifier probes may be immersed in  
5 nucleic acid amplification buffer comprising amplification components. Setting of denaturing conditions will set free the bound identifier probes which then may be essentially simultaneously amplified.

Probe amplification involves the amplification (i.e. replication) of the identifier probe  
10 sequence being bound to the immobilized sample genomic nucleic acids, resulting in a significant increase in the number of identifier probe molecules.

Although numerous amplification techniques are known in the art, a particular suitable amplification technique employs a single primer pair, whereby each member  
15 of said primer pair is complementary to a primer binding sequence which is positioned flanking 5' or 3' to each identifier probe; said 5' and 3' flanking primer binding sequences being the same or substantially the same for each probe.

Accordingly, in one embodiment of the present invention, a method for hybridisation  
20 of probes onto immobilized genomic DNA is provided wherein the probes are flanked by primer binding sequences,

As used herein, "amplification" refers to the increase in the number of copies of a particular nucleic acid of interest wherein said copies are also called "amplicons" or  
25 "amplification products". In particular, by amplification is meant a technique for linearly or exponentially increasing the copy number of a nucleic acid molecule.

In one embodiment of the present invention, a hybridisation method is provided wherein the amplification of the recovered hybridised probes is a quantitative  
30 amplification.

The requirement for sensitivity (i.e. low detection limits) has been greatly alleviated by the development of the polymerase chain reaction (PCR) and other amplification technologies, which allow researchers to amplify exponentially a specific nucleic acid  
35 sequence before analysis. Suitable amplification methods include exponential amplification methods such as for example PCR, quantitative PCR (Q-PCR), biotin

capture PCR as well as linear amplification methods such as for example linear amplification by *in vitro* transcription TYRAS and NASBA.

5 In a further embodiment of the present invention, a hybridisation method is provided wherein said amplification is by means of polymerase chain reaction.

The polymerase chain reaction (PCR) is widely used and described, and involves the use of primer extension combined with thermal cycling to amplify a target sequence; see US 4,683,195 and US 4,683,202, and PCR Essential Data, J. W. Wiley & sons,  
10 Ed. C. R. Newton, 1995, all of which are incorporated by reference.

Suitable PCR-based amplification strategies are well known in the art and may be, by way of example and not limitation, routine quantitative PCR (QC-PCR), reverse transcriptase PCR or RT-PCR, biotin capture PCR, nucleic acid sequence based  
15 amplification (NASBA), and TYRAS.

The TYRAS amplification method as disclosed in WO 99/43850, hereby incorporated by reference, is a non-selective poly-A mRNA amplification method which does not encompass cDNA synthesis. The method comprises the hybridisation of an  
20 oligonucleotide, encompassing an oligo-T stretch, to the poly-A tail of the mRNA followed by RNase H digestion opposite the oligonucleotide and extension of the newly formed 3' end of the mRNA with reverse transcriptase. In this way the T7 RNA polymerase recognition sequence (i.e. T7 promoter) that is part of the oligonucleotide encompassing an oligo-T stretch is made double stranded. Upon binding of the T7  
25 RNA polymerase to the promoter the original mRNA molecules are transcribed in multiple RNA copies of the opposite polarity.

RNA may also be amplified according to the method as disclosed in US Patent No 5,545,522 (Van Gelder), hereby incorporated by reference, wherein cDNA is  
30 synthesized from an RNA sequence using a complementary primer linked to an RNA polymerase promoter region complement and then antisense RNA (aRNA) is transcribed from the cDNA by introducing an RNA polymerase capable of binding to the promoter region.

35 Nucleic acid sequence based amplification (NASBA) is generally described in US 5,409,818 and "Profiting from Gene-based Diagnostics", CTB International Publishing Inc., N.J., 1996, both of which are incorporated by reference. NASBA relies on the

simultaneous activity of 3 enzymes: AMV-RT (Avian Myoblastosis Virus-Reverse Transcriptase), RNase H and T7 RNA polymerase. NASBA is a special case of the 3SR amplification reaction or self-sustained sequence replication-reaction.

- 5 The 3SR reaction is a very efficient method for Isothermal amplification of target DNA or RNA sequences in vitro. This method requires three enzymatic activities: reverse transcriptase, DNA-dependent RNA polymerase and *Escherichia coli* ribonuclease H.

10 For use in multiplex PCR, a primer should be designed so that its predicted hybridisation kinetics are similar to those of the other primers used in the same multiplex reaction. While the annealing temperatures and primer concentrations may be calculated to some degree, conditions generally have to be empirically determined for each multiplex reaction. Since the possibility of non-specific priming increases with each additional primer pair, conditions must be modified as necessary as  
15 individual primer sets are added. Moreover, artefacts that result from competition for resources (e.g. depletion of primers) are augmented in multiplex PCR, since differences in the yields of unequally amplified fragments are enhanced with each cycle.

- 20 As well known by the person skilled in the art, probe design for multiplex PCR may encompass flanking primer binding sequences that do not hybridise to the target sequence to overcome the above-mentioned draw-backs.

25 Accordingly, in one embodiment of the present invention, a method for target nucleic acid detection and quantification in a genomic DNA sample is provided, wherein each probe is flanked 5' and 3' by primer binding regions with said 5' and 3' flanking primer binding sequences being the same or substantially the same for each probe.

30 By target sequence or target nucleic acid is meant a nucleic acid sequence that a probe is designed to detect; e.g., for an "identification"-probe, the target sequence might be an identification sequence. By identification sequence is meant a nucleic acid sequence that is diagnostic of a particular organism or group of organisms or that is diagnostic for a particular genetic disease state when its presence or existence is assayed in a genome or enriched genome by hybridisation using the  
35 appropriate melting temperature criteria. By an enriched genome or enriched genomic fraction, is meant a genome or genomic fraction that has undergone an enrichment procedure that generates a selected fraction of the original genome. For



example, for the purpose of genomic profiling, enriched genomes offer robust hybridisation-based diagnostics.

5 The set of identifier or identification probes or polynucleotides may correspond to particular mutations that are to be identified in a known sequence. As such, for a known gene that may contain any of several possible identified mutations, the set can comprise polynucleotides corresponding to the different possible mutations. This is, for instance, useful for genes like oncogenes and tumour suppressors, which frequently have a variety of known mutations in different positions.

10

In one embodiment of the present invention, a method for target nucleic acid detection and quantification in a genomic DNA sample is provided, wherein the amplified probes are provided with a label.

15 The term label as used in the present specification refers to a molecule propagating a signal to aid in detection and quantification. Said signal may be detected either visually (e.g., because it has a coloured product, or emits fluorescence) or by use of a detector that detects properties of the reporter molecule (e.g., radioactivity, magnetic field, etc.). In the present specification, labels allow for the detection of the  
20 identification and quantification of target sequences within a genomic sample. Detectable labels suitable for use in the present invention include but are not limited to any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means.

25 Accordingly, virtually any label that produces a detectable, quantifiable signal and that is capable of being attached to a nucleotide and incorporated into the generated amplicon, can be used in conjunction with the methods of the invention. Suitable labels include, by way of example and not limitation, radioisotopes, fluorophores, chromophores, chemiluminescent moieties, chemical labelling such as ULS labelling  
30 (Universal Linkage system; Kreatech) and ASAP (Accurate, Sensitive and Precise; Perkin Elmer), etc. Suitable labels may induce a colour reaction and/or may be capable of bio-, chemi- or photoluminescence.

35 Means for detecting such labels are well known to those of skill in the art. Thus, for example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted illumination. Enzymatic labels are typically detected by providing the enzyme

with an enzyme substrate and detecting the reaction product produced by the action of the enzyme on the substrate; colorimetric labels are detected by simply visualizing the coloured label, and chemical labels by for example a platinum group form coordinative bonds with the labelling target, firmly coupling the label to the target.

5

Preferably, the position of the label will not interfere with generation, hybridisation, detection or other post-hybridisation modification of the labelled polynucleotide. A variety of different protocols may be used to generate the labelled nucleic acids, as is known in the art, where such methods typically rely on the labelled primers, or enzymatic generation of labelled nucleic acid using a labelled nucleotide. For instance, label may be incorporated into a nucleic acid during amplification steps in order to produce labelled amplicons. Alternatively, the generated amplicons may be labelled after the amplification.

10

A variety of labels may be employed, where such labels include fluorescent labels, isotopic labels, enzymatic labels, chemical labels, electron-dense reagents, particulate labels, etc. For example, suitable isotopic labels include radioactive labels, e.g.  $^{32}\text{P}$ ,  $^{33}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{14}\text{C}$ . For example, suitable enzymatic labels include glucose oxidase, peroxidase, uricase, alkaline phosphatase etc. Other suitable labels include size particles that possess light scattering.

20

Fluorescent labels are particularly suitable because they provide very strong signals with low background. Fluorescent labels are also optically detectable at high resolution and quick scanning procedure. Fluorescent labels offer the additional advantage that irradiation of a fluorescent label with light can produce a plurality of emissions. Thus, a single label can provide for a plurality of measurable events.

25

Accordingly, in a further embodiment of the present invention, a method for target nucleic acid detection and quantification in a genomic DNA sample is provided, wherein the amplified probes are provided with a fluorescent label.

30

Desirably, fluorescent labels should absorb light above about 300 nm, usually above about 350 nm, and more usually above about 400 nm, usually emitting at wavelengths greater than about 10 nm higher than the wavelength of the light absorbed.

35

Particular useful fluorescent labels include, by way of example and not limitation, fluorescein isothiocyanate (FITC), rhodamine, malachite green, Oregon green, Texas Red, Congo red, SybrGreen, phycoerythrin, allophycocyanin, 6-carboxyfluorescein (6-FAM), 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein (JOE), 6-carboxy X-rhodamine (ROX), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 5-carboxyfluorescein (5-FAM), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), cyanine dyes (e.g. Cy5, Cy3), BODIPY dyes (e.g. BODIPY 630/650, Alexa542, etc.), green fluorescent protein (GFP), blue fluorescent protein (BFP), yellow fluorescent protein (YFP), red fluorescent protein (RFP), and the like, (see, e.g., Molecular Probes, Eugene, Oregon, USA).

In one embodiment, the use of a method according to the present invention and as described herein is provided for detection and quantification of target nucleic acids in a genomic DNA sample.

Yet another object of the present invention is to provide for a method for target nucleic acid detection and quantification in a genomic DNA sample comprising the steps of: (a) providing genomic DNA and denaturing said genomic DNA; (b) performing a hybridisation according to a method as described within the present specification; (c) recovering hybridised probes; and essentially simultaneously amplifying any recovered probe using a single primer pair, each member of said primer pair binding to each recovered probe onto the respective flanking primer binding sequences of said probe; and (d) qualitatively and quantitatively analysing the recovered amplified probes of step (c).

Recovered amplified probes may be analysed by gel electrophoresis. However, for improved reproducibility and accuracy of procedures, an automated system for determining genomic profiles is contemplated. In particular, the present invention connotes the use of a probe array or microarray which is interrogated with the amplified hybridised identifier probes provided by the methods of the invention. The term "probe array" relates to a substrate having a high density matrix pattern of positionally defined specific recognition reagents. The multiple probe copies provided by the method of the invention are capable of interacting, e.g. hybridising, with their specific counterparts, i.e. the specific recognition reagents, on the array. Because the specific recognition reagents are positionally defined, the sites of interaction will define the specificity of each interaction. The specific recognition reagents will typically be deoxyribonucleotide (DNA) probes, in which case said probe array is

known as an oligonucleotide or cDNA array. Various array production methods are known in the art.

Accordingly, in a further embodiment of the present invention, a method for target  
5 nucleic acid detection and quantification in a genomic DNA sample is provided, wherein the analysis of the recovered amplified probes is by microarray analysis.

The term "nucleic acid" as used herein means a polymer composed of nucleotides, e.g. deoxyribonucleotides or ribonucleotides. The terms "deoxyribonucleic acid" and  
10 "DNA" as used herein means a polymer composed of deoxyribonucleotides. The term "oligonucleotide" as used herein denotes single stranded nucleotide multimers of from about 10 to about 100 nucleotides in length. The term "polynucleotide" as used herein refers to single or double stranded polymer composed of nucleotide monomers of from about 10 to about 5000 nucleotides in length, usually of greater  
15 than about 100 nucleotides in length up to about 1000 nucleotides in length.

For a given substrate size, the upper limit is determined only by the ability to create and detect the spots in the array. The preferred number of spots on an array generally depends on the particular use to which the array is to be put. For example,  
20 mutation detection may require only a small array. In general, arrays contain from 2 to about  $10^6$  spots, or from about 4 to about  $10^5$  spots, or from about 8 to about  $10^4$  spots, or between about 10 and about 2000 spots, or from about 20 to about 200 spots.

25 Suitable arrays may be of any desired size, from two spots to  $10^6$  spots or even more. The upper and lower limits on the size of the substrate are determined solely by the practical considerations of working with extremely small or large substrates.

The immobilized polynucleotides may be as few as four, or as many as hundreds, or  
30 even more, nucleotides in length. Contemplated, as polynucleotides according to the invention are nucleic acids that are typically referred to in the art as oligonucleotides and also those referred to as nucleic acids. Thus, the arrays within the present invention are useful in applications where the generated identifier probe copies are hybridised to immobilized arrays of relatively short (such as, for example, having a  
35 length of approximately 6, 8, 10, 20, 40, 60, 80, or 100 nucleotides) detector probes.

The detector polynucleotides can be immobilized on the substrate using a wide variety of techniques. For example, the polynucleotides can be adsorbed or otherwise non-covalently associated with the substrate (for example, immobilization to nylon or nitrocellulose filters using standard techniques); they may be covalently  
5 attached to the substrate; or their association may be mediated by specific binding pairs, such as biotin and streptavidin.

A number of materials suitable for use as substrates for microarray analysis purposes in the instant invention have been described in the art. Exemplary suitable materials  
10 include, for example, acrylic, styrene-methyl methacrylate copolymers, ethylene/acrylic acid, acrylonitrile-butadienestyrene (ABS), ABS/polycarbonate, ABS/polysulfone, ABS/polyvinyl chloride, ethylene propylene, ethylene vinyl acetate (EVA), nitrocellulose, nylons (including nylon 6, nylon 6/6, nylon 6/6-6, nylon 6/9, nylon 6/10, nylon 6/12, nylon 11 and nylon 12), polycarylonitrile (PAN), polyacrylate,  
15 polycarbonate, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polyethylene (including low density, linear low density, high density, cross-linked and ultra-high molecular weight grades), polypropylene homopolymer, polypropylene copolymers, polystyrene (including general purpose and high impact grades), polytetrafluoroethylene (PTFE), fluorinated ethylene-propylene (FEP), ethylene-  
20 tetrafluoroethylene (ETFE), perfluoroalkoxyethylene (PFA), polyvinyl fluoride (PVF), polyvinylidene fluoride (PVDF), polychlorotrifluoroethylene (PCTFE), polyethylene-chlorotrifluoro-ethylene (ECTFE), polyvinyl alcohol (PVA), silicon styreneacrylonitrile (SAN), styrene maleic anhydride (SMA), and glass.

25 Other exemplary suitable materials for use as substrates in the arrays of the present invention include metal oxides. Metal oxides provide a substrate having both a high channel density and a high porosity, allowing high density arrays comprising different specific recognition reagents per unit of the surface for sample application. In addition, metal oxides are highly transparent for visible light. Metal oxides are  
30 relatively cheap substrates that do not require the use of any typical microfabrication technology and, that offers an improved control over the liquid distribution over the surface of the substrate, such as electrochemically manufactured metal oxide membrane. Metal oxide membranes having through-going, oriented channels can be manufactured through electrochemical etching of a metal sheet. Metal oxides  
35 considered are, among others, oxides of tantalum, titanium, and aluminium, as well as alloys of two or more metal oxides and doped metal oxides and alloys containing metal oxides. The metal oxide membranes are transparent, especially if wet, which

allows for assays using various optical techniques. Such membranes have oriented through-going channels with well-controlled diameter and useful chemical surface properties. Patent application EP-A-0 975 427 is exemplary in this respect, and is specifically incorporated in the present invention.

5

As will be appreciated in the art, methods according to the present invention find particular use in methods for genomic screening and gene expression studies. For example, genomic DNA or RNA can be immobilized onto a matrix as described herein and flow-through hybridised with for example two antisense oligonucleotides which leave a 10 base gap between them upon hybridisation onto a target sequence. By use of DNA polymerase in the presence of the necessary dNTPs, said gap will be filled which may then subsequently be ligated. Un-hybridised probes are then flow-through washed off through said matrix after which the hybridised oligonucleotides are eluted, quantitatively amplified and analysed by means of a microarray. As another example, genomic DNA or RNA can be immobilized onto a matrix as described herein and flow-through hybridised with for example short PCR-amplified probes.

It is another object of the invention to provide for the use of a method according to the present specification and as described herein is provided for genomic screening.

By the term "genomic screening" is meant the screening for genetic variability within for example a genetic locus. Mutations may be located within genes for a variety of scenarios: e.g., for detecting sequence changes of HIV mutants which generate drug resistance and for detecting sequence changes of genes in relation to cancer development. Said sequence changes may include for example sequence deletions and sequence duplications.

Accordingly, in a further embodiment, the use of a method according to the present invention and as described herein is provided for detecting deletions or duplications in genomic DNA.

In a further embodiment, the use of a method according to the present invention and as described herein is provided for genome profiling.

35

By the term "genome profiling" is meant the identification of the presence and/or absence of genomic differences or variation between genomes of closely related

species such as for example between humans and other primates. Genome profiling encompasses the identification of species using genotypes (genotyping).

5 In a further embodiment, the use of a method according to the present invention and as described herein is provided for identifying and quantitatively detecting the degree of pathogenesis, disease or contamination in a sample.

10 In a further embodiment, the use of a method according to the present invention and as described herein is provided for identifying and detecting the presence of infectious agents in a sample.

In a further embodiment, the use of a method according to the present invention and as described herein is provided for genotyping pathogens present in a sample.

15 The present invention also provides kits for performing the subject flow-through hybridisation methods. The subject kits at least include a device for flow-through hybridisation of probes onto immobilized genomic DNA comprising a well holder, said well holder comprising one or more round wells with a fixed diameter, said wells exposing a fibre network matrix.

20 Accordingly, it is a further object of the present invention to provide a kit for flow-through hybridisation of probes onto immobilized genomic DNA comprising a device for flow-through hybridisation according as described in the present specification and instructions to carry out a method according to the specifications as described herein.

25 Kits may further comprise one or more reagents employed in the various methods, such as amplification primers for generating amplicons of the hybridised identifier probes as well as the amplification components. As used herein, the term "amplification components" refers to the reaction reagents such as enzymes, buffers,  
30 and nucleic acids including nucleotides necessary to perform an amplification reaction to form amplicons or amplification products of the hybridised identifier probes. A primer is a nucleic acid molecule with a 3' terminus that is either "blocked" and cannot be covalently linked to additional nucleic acids or that is not blocked and possesses a chemical group at the 3' terminus that will allow extension of the nucleic  
35 acid chain such as catalysed by a DNA polymerase or reverse transcriptase.

Accordingly, in one embodiment of the present invention a kit for target nucleic acid detection in a genomic DNA sample is provided additionally comprising (a) a set of probes, wherein each probe is flanked 5' and 3' by primer binding regions with said 5' and 3' flanking primer binding sequences being the same or substantially the same for each probe; (b) a single primer pair, each member of said pair being complementary to a primer binding region; (c) optionally amplification components allowing the amplification of any recovered hybridised probe; and (d) optionally a microarray, said microarray allowing analysis of the hybridisation results obtained by a method as described within the present specification.

10

### Short Description of the Figures

**Figure 1** shows a schematic representation of the hybridisation method of the present invention. Genomic material is first immobilized onto a suitable matrix such that said genomic material becomes permeated within said matrix material (step 1). A set of identifier probes is subsequently hybridised by flow-through onto the immobilized genomic material (step 2) to arrive at the formation of hybridised genomic DNA/probe complexes (step 3). Unbound probes are washed off by flow-through washing (step 4), leaving said formed hybridised genomic DNA/probe complexes (step 5) for further analysis (step 6).

15

20

**Figure 2** illustrates the electrophoresis results of the PCR products corresponding to 12 control probes as prepared according to the description in Example 1, paragraph 1.1.1. Probe numbers, probe names, probe sizes and genomic locations are as mentioned in Table 1.

25

M, 100bp DNA ladder (Cat. No. 15628-050; Invitrogen).

**Figure 3** illustrates the electrophoresis results of the PCR products corresponding to the *MSH2* probes that were prepared from direct amplification of human genomic DNA using 18 specific primer pairs flanked by the same sequences as PZA and PZB as described in Example 1, paragraph 1.1.2. The sequences of the 18 specific *MSH2* primer pairs for PCR amplification are as mentioned in Table 2.

30

M, 100bp DNA ladder; Q, negative control.

**Figure 3A** illustrates said results after PCR in PCR mixture without DMSO;

35

**Figure 3B** illustrates said results after PCR in PCR mixture with DMSO.



**Figure 4** illustrates the electrophoresis results of the PCR products after flow-through hybridisation of 1 µg of immobilized genomic DNA from healthy control individual 1 with a control probe mixture in formamide hybridisation solution as described in Example 1, paragraph 1.3.

5 a, first PCR; b, repeat PCR reaction from the same multiplex amplifiable probe hybridisation solution; M, 100bp DNA ladder; P, PCR from control probe mix; Q, negative control for PCR; W, water control for hybridisation; 1, genomic DNA from healthy control individual 1. No PCR products were obtained from the negative controls from PCR and hybridisation.

10

**Figure 5** illustrates the electrophoresis results of the PCR products after flow-through hybridisation of 250ng of immobilized genomic DNA from three healthy control individuals (Individuals 1, 4, and 5).

M, 100bp DNA ladder; P, PCR from control probe mix; Q, negative control for PCR;  
15 W, water control for hybridisation. No PCR products were obtained from the negative controls from PCR and hybridisation.

**Figure 6** illustrates the quality control of amplified probes as described in Examples 1 and 2.

20

**Figure 6<sub>A-C</sub>** illustrates gel-electrophoresis results of the quality control of 12 control probes, 18 *MSH2* probes and 19 *MLH1* probes.

## EXAMPLES

The following examples of the invention are exemplary and should not be taken as in  
25 any way limiting.

### Example 1: Flow-through hybridisation of genomic DNA

#### 1.1 Probe preparation

30

##### 1.1.1 Probe preparation – control probes

Plasmids (100ng/µl) were obtained from the Institute of Genetics, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK (Dr. John Armour). Probe DNA was amplified from these plasmids using flanking vector primers PZA (AGTAACGGCCGCCAGTGTGCTG; SEQ ID No. 1) and PZB  
35 (CGAGCGGCCGCCAGTGTGATG; SEQ ID No. 2) (Isogene).

The PCR reaction was performed (PTC-200 Peltier Thermal Cycler; MJ Research INC; Massachusetts, USA) in a reaction mixture comprising 5µl 10x PCR gold buffer (PE) (Cat. No.4311816; Applied Biosystems), 2.5µl MgCl<sub>2</sub> (25mM), 1.25µl dNTPs (10mM; Amersham Pharmacia Biotech), 0.125µl AmpliTaq Gold® (5 U/µl) (Cat. No.4311816; Applied Biosystems), 1µl PZA forward primer (10pM), 1µl PZB reverse primer (10pM), 1µl plasmid DNA, and 38.125µl HLPC-water. A PCR program with following cycle order was completed: cycle 1, 3 min at 94°C; cycles 2 to 35, 1 min at 94°C, 1 min at 60°C, 1 min at 72°C; and finally 10 min at 72°C.

Obtained PCR products were purified using the Qiaquick PCR purification kit (Cat. No.28106, QIAGEN, Germany) and dissolved in 300µl EB buffer (10mM Tris-Cl, pH8.5).

A 40-times dilution was made up from the purified PCR products (5µl PCR products + 195µl water) for DNA concentration measurement using a SpectramaxPlus 384 reader (Molecular Devices; Sunnyvale, CA, USA). The following concentrations were obtained: probe 1, 27ng/µl; probe 2, 26ng/µl; probe 3, 23ng/µl; probe 4, 11ng/µl; probe 5, 5ng/µl; probe 6, 12ng/µl; probe 7, 13ng/µl; probe 8, 13ng/µl; probe 9, 19ng/µl; probe 10, 6ng/µl; probe 11, 22ng/µl and probe 12, 5ng/µl.

Subsequently, 10µl PCR products were loaded on a 2% agarose gel in 400mM Tris-Acetate/10mM EDTA (TAE) (0.5x; Cat. No. 15558-042; GIBCOBRL). Electrophoresis was performed at 100V for 40 min (Figure.2).

Probe names, sizes and sequences are given in Table 1.

#### 1.1.2 Probe preparation – MSH2 probes

Genomic DNA 1 was obtained from a healthy control individual via the blood bank of the University Hospital of Leiden, The Netherlands. *MSH2* probes were prepared by PCR on genomic DNA 1. The *MSH2* primers used are shown in Table 2.

PCR was performed in a reaction mixture comprising 5µl PCR Gold buffer (10X), 2.5µl MgCl<sub>2</sub> (25mM), 1.25µl dNTPs (10mM), 0.125µl AmpliTaq Gold (5U/µl), 1µl *MSH2* forward primer (10pM), 1µl *MSH2* reverse primer (10pM), 1µl genomic DNA (100ng/µl), and 38.125µl HLPC-water.

Additionally, a second PCR mixture was made up including 5µl DMSO.

A PCR program with following cycle order was completed: cycle 1, 3 min at 94°C; cycles 2 to 5, 1 min at 94°C, 1 min at 56°C, 1 min at 72°C; cycles 6 to 10, 1 min at

94°C, 1 min at 53°C, 1 min at 72°C; cycles 11 to 35, 1 min at 94°C, 1 min at 50°C, 1 min at 72°C; and finally 10 min at 72°C.

Obtained PCR products were purified using the Qiaquick PCR purification kit and dissolved in 300µl EB buffer (10mM Tris-Cl, pH 8.5). A 40-times dilution was made up from the purified PCR products (5µl PCR products + 195µl water) for DNA concentration measurement using a SpectramaxPlus reader. Subsequently, 10µl PCR products were loaded on a 2% agarose gel in TAE (0.5X). Electrophoresis was performed at 100V for 40 min (Figure 3).

### 1.2 Poly-L-lysine (PLL) coating of Whatman 3MM Chr paper

Whatman 3MM Chr paper (cat No. 3030 917) was cut into small pieces and 50 of them were placed in a Teflon holder (see WO 02/072268 for further specifications on said holder). A 0.01% poly-L-lysine solution was prepared with 35ml Poly-L-lysine (0.1%, Sigma; Cat. No. P 8920), 35 ml PBS (1X), and 280ml filtered HLPC water. This 350ml PLL solution was subsequently poured in a 600ml beaker which was placed on a plate shaker. The holder was gently moved up and down to prevent that air bubbles would be enclosed between the holder and the Whatman papers. The beaker was closed with parafilm and incubated on the plate shaker at room temperature with shaking at 100 rpm for 1 hour. Subsequently, Whatman papers were transferred to a second beaker filled with 350ml HLPC-water; the holder was again moved gently up and down for a couple of times. This transfer was repeated at least one more time. Papers were then transferred to an aluminium foil dish and placed for 2 hours in a vacuum oven at 37°C under vacuum. After turning off the vacuum pump, papers were allowed to cool down to room temperature after which they were stored in a dark and dry place.

### 1.3 Genomic DNA hybridisation on Whatman 3MM Chr paper coated with PLL whereby washing is performed with a reduced washing volume

#### 1.3.3. Solutions

50% deionised formamide hybridisation solution was prepared by mixing together 5ml formamide (100% deionised), 1.5ml SSC (20X), 0.5ml SDS (20%), 1ml Denhardts solution (100X), 20µl Tween-20, and 1.8ml HLPC-water. Pre-hybridisation buffer was prepared by drying 10µl herring sperm DNA (10µg/µl) using a SpeedVac for 15min and adding 50µl of hybridisation buffer to this dried herring sperm DNA. Probe mixture was prepared by mixing 4µl control probe mix (10ng/each probe), 20µl Cot-1 DNA, and 1ul blocker (50pmol/µl) of PZAX

(AGTAACGGCCGCCAGTGTGCTGGAATTCTGCAGAT; SEQ ID No. 3) / PZBX (CGAGCGGCCGCCAGTGTGATGGA; SEQ ID No. 4), Cot-1 DNA (Cat. No.1581074; Roche) was used to block repetitive sequences of human genomic DNA for specific hybridisation. The probe mix was dried using a SC110A-240 SpeedVac Plus  
 5 (Savant Instrument INC; New York, USA) for 15min after which 50µl of hybridisation buffer was added.

### 1.3.2 Genomic DNA hybridisation on Whatman 3MM Chr paper coated with PLL

A Whatman paper slide was made onto which 1µg denatured genomic DNA of  
 10 control 1 was spotted. Water was spotted as control on an individual paper. The DNA was allowed to dry for 10 min at room temperature. The DNA was subsequently UV cross-linked (UV Stratalinker 1800; Cat. No.400072; Stratagene; California, USA) to the Whatman papers at 50 mJ on both sides. 50% deionised formamide hybridisation solution was prepared by mixing together 5ml formamide (100% deionised), 1.5ml  
 15 SSC (20x), 0.5ml SDS (20%), 1ml Denhardt's solution (100x), 20µl Tween-20, and 1.8ml HPLC-water. The pre-hybridisation solution consisting of 100µg herring sperm DNA (10µg/µl; Cat. No.D1816; Promega) in hybridisation solution was boiled for 5 min and placed on ice. Whatman papers were pre-hybridised in 50µl pre-hybridisation solution at 42°C for 2 hours using flow-through system (0.2 bar  
 20 pressure at 42°C for 2 hours at 2 cycles/min). The pre-hybridisation solution was removed followed by a washing step once with hybridisation buffer.

The hybridisation probe mix was boiled for 5 min and placed on ice. 50µl hybridisation probe mix solution was added and incubated at 42°C for 4 hours using  
 25 the flow-through system.

### 1.3.3 Post-hybridisation washes

The hybridisation mix was pipetted off and the Whatman papers were washed using flow-through system at 42°C using 25ml of solution 1 for 2.5 min and 25ml of solution  
 30 2 for 2.5 min. Wash solution 1 consisted of 1% SSC (20x SSC, 3M NaCl, 0.3M Sodium Citrate) and 1% SDS and wash solution 2 consisted of 0.1% SSC and 0.1% SDS.

Individual Whatman papers were transferred into 50µl of PCR buffer (1x) in 1.5ml  
 35 tubes and each boiled for 5 min. 5µl of the boiled solution was transferred into a tube with PCR mixture comprising 5µl PCR gold buffer (10x), 2.5µl MgCl<sub>2</sub> (25mM), 1.25 µl

dNTPs (10mM), 0.125  $\mu$ l AmpliTaq Gold (5U/ $\mu$ l), 1 $\mu$ l PZA Forward primer (10pM), 1 $\mu$ l PZB reverse primer (10pM), 5 $\mu$ l sample solution, and 34.125 $\mu$ l HLPC-water.

A PCR program with following cycle order was completed: cycle 1, 3 min at 94°C; cycles 2 to 35, 1 min at 94°C, 1 min at 60°C, 2 min at 72°C; and finally 10 min at 72°C. 10 $\mu$ l PCR products were loaded onto a 2% agarose gel with TAE (0.5X). Electrophoresis was performed at 100V for 40 min. The results are shown in Figure 4.

In conclusion, the above experiment demonstrates that multiplex amplification probe hybridisation can be performed by flow-through hybridisation on genomic DNA immobilized within a matrix or membrane structure.

#### 1.4 Genomic DNA hybridisation on Whatman 3MM Chr paper coated with PLL using control probes

##### 1.4.1 Solutions

50% deionised formamide hybridisation solution was prepared by mixing together 5ml formamide (100% deionised), 1.5ml SSC (20x), 0.5ml SDS (20%), 1ml Denhardt's solution (100x), 20 $\mu$ l Tween-20, and 1.8ml HLPC-water. Pre-hybridisation buffer was prepared by drying 10 $\mu$ l herring sperm DNA (10 $\mu$ g/ $\mu$ l) using a SpeedVac for 15min and adding 30 $\mu$ l of hybridisation buffer to this dried herring sperm DNA. Probe mixture was prepared by mixing 4 $\mu$ l PMP22 control probe mix (10ng/each probe), 20 $\mu$ l Cot-1 DNA (1mg/ml), and 1 $\mu$ l PZAX/PZBX blocker (50pmol/ $\mu$ l). The end-blocking primers PZAX and PZBX as described in Example 1, paragraph 1.3 (Isogene) were added to prevent cross-hybridisation between different probes used in the same mixture. The probe mix was dried using a SpeedVac for 15min after which 30 $\mu$ l of hybridisation buffer was added.

##### 1.4.2 Genomic DNA hybridisation on Whatman 3MM Chr paper coated with PLL

250ng of denatured genomic DNA of control individuals 1, 4 and 5 was spotted onto individual PLL-coated paper. Water was spotted as control on an individual paper.

The DNA was allowed to dry for 10 min at room temperature. The DNA was subsequently UV cross-linked to the Whatman papers at 50 mJ on both sides. The pre-hybridisation solution was boiled for 5 min and placed on ice. Whatman papers were pre-hybridised in 30 $\mu$ l pre-hybridisation solution at 42°C for 2 hours using flow-through system (at 0.2 bar and 2 cycles/min). The pre-hybridisation solution was

removed followed by a washing step once with hybridisation buffer.

The hybridisation probe mix was boiled for 5 min and placed on ice. 30µl hybridisation probe mix solution was added and incubated at 42°C for 4 hours using the flow-through system.

#### 1.4.3 Post-hybridisation washes

Wash solutions were prepared as before.

The hybridisation mix was pipetted off and the Whatman papers were washed using flow-through system at 65°C using 50ml of solution1 and 50ml of solution 2 for 10 min. Individual Whatman papers were transferred into 50µl of PCR buffer (1x) in 1.5ml tubes and each boiled for 5 min. 5µl of the boiled solution was transferred into a tube with PCR mixture comprising 5µl PCR gold buffer (10x), 3µl MgCl<sub>2</sub> (25mM), 5µl dNTPs (2.5mM), 0.125µl AmpliTaq Gold (5U/µl), 1µl PZA Forward primer (10pM), 1µl PZB reverse primer (10pM), 5µl sample solution, and 22.375µl HLPC-water. A PCR program with following cycle order was completed: cycle 1, 3 min at 94°C; cycles 2 to 35, 1 min at 94°C, 1 min at 60°C, 2 min at 72°C; and finally 10 min at 72°C. 10µl PCR products were loaded onto a 2% agarose gel with TAE (0.5x). Electrophoresis was performed at 100V for 40 min. The results are shown in Figure 5.

In conclusion, the above experiment demonstrates that strong PCR bands were obtained upon electrophoresis of PCR products after flow-through hybridisation of genomic DNA from individuals 1, 4 and 5 with the control probes.

#### **Example 2: Application of the present invention in the analysis of sample genomic DNA for hereditary nonpolyposis colorectal cancer.**

Colorectal cancer is one of the most common cancers in both men and women. The majority of the hereditary colorectal cancers is hereditary nonpolyposis colorectal cancer (HNPCC). HNPCC is an autosomal dominant disorder caused by mutations in mismatch repair (MMR) genes. The large majority of germline mutations detected in HNPCC families occur in the *MSH2* and *MLH1* genes. Approximately 25% of the germline mutations found in the *MSH2* and *MLH1* genes are large genomic deletions.

Identification of germline mutations in the MMR genes will open the possibility of pre-symptomatic diagnosis in members of affected families. The results of a genetic screening will influence medical management of the patient or family members.

## 2.1 Preparation and quality control of the probes for microarray production

The probes of *MSH2* P1 and P2 were generated from direct amplification of human genomic DNA prepared as described in Example 3. The probes (12 control probes, 16 *MSH2* probes and 19 *MLH1* probes) were generated from amplification of plasmids using the flanking vector primers PZA and PZB as described in Example 2.

These plasmids were obtained from the Institute of Genetics, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK. The probes (12 control, 16 *MSH2* and 19 *MLH1*) were prepared by cloning PCR products into the EcoRV site of pZero2 (Invitrogen). The sequences of the control probes that were cloned into the plasmids can be found in Table 1. The sequences of the *MSH2* and *MLH1* that were cloned into the plasmids can be found in Tables 3 and 4 respectively. Probe quality was monitored by gel electrophoresis onto a 2% agarose gel with TAE (0.5x) at 100V for 40 min of which the results are shown in Figures 6A-C.

Control probes are used for normalization of microarray data and checking for PCR contamination. Human *MSH2* is located on chromosome 2p21 and has 16 exons. The 18 *MSH2* probes represent the 16 exons and two *MSH2* promoter regions (P1 and P2). Human *MLH1* is located on chromosome 3p21 and has 19 exons. The 19 *MLH1* probes represent the 19 exons.

After flow-through hybridisation according to the present invention and post-hybridisation washes as described above, individual Whatman papers will be transferred in 50µl of PCR buffer (1x) in 1.5ml tubes and each boiled for 5 min. 5µl of the boiled solution is then subsequently transferred into a tube with PCR mixture comprising 5µl PCR gold buffer (10x), 3µl MgCl<sub>2</sub> (25mM), 5µl dNTPs (2.5mM), 0.125µl AmpliTaq Gold (5U/µl), 1µl PZA forward primer (10pM), 1µl PZB reverse primer (10pM), 5µl sample solution and 22.375µl HLPC water. A PCR program with following cycle order will be performed; cycle 1, 3 min at 94°C; cycles 2 to 35, 1 min at 94°C, 1 min at 60°C, 2 min at 72°C; and finally 10 min at 72°C.

During PCR amplification, labelled primer(s) or enzymatic generation of labelled nucleic acid will be used to generate labelled nucleic acids. The obtained labelled

PCR products can then be purified using the Qiaquick purification kit and dissolved in 50 µl of EB buffer (10mM Tris-Cl, pH 8.5) for further detection using a microarray.

5 Alternatively, chemical labels can be used (Kreatech) whereby for example a platinum group forms a coordinative bond with the labelling target, firmly coupling the label to the target.

10 For analysis of HNPCC patients, 49 of 60-mer oligo's (12 control, 18 *MSH2* and 19 *MLH1*) having 40% to 50% GC content (Eurogentec) were selected for production of a microarray. The sequences of the oligo's can be found in Table 5. Upon manufacturing of a HNPCC microarray, clinical samples from patients with HNPCC can be analysed.



Table 1. SEQ ID Nos, names, sizes and genomic location of the control probes

SEQ ID NO.	Probe Name	Probe Size (bp)	Location	Sequence
5	8D2	522	Sub-telomeric (chrom. 19)	CTGAGGGGCAATCAAGCTCTGCGCCCTGGGGTTGGCCCTGGAGATGGCCCTCACCTTTTCCAGGACACAGCAGGTGGCCACGAGC CCACAACCACTTACACAGCCACAGCGGTGTGAAGCAGGGAAGCATCTTAAGTACCTCTGAATACCCCTCAGCCCCCTTAGGACCT CTGGTAGGGGTGAGGACAGGTTCTCTGGGCAACGGTTCTCTCCTCAGTCAGGGGCTGGTTTCTACTCCGCAACCCAGGAGCCTGACTACAA GGGATGGCAGGACCAATCAATGAGGCCCAAGTCTGAGCGGCAAGTTGAACAAGTCGCGAGGCTTGAGATCCACACCGAGTAACAGGGA GTTAACAATATGGCCCCAGGAGAGGTGGTCTGCAGGGTCTGAGGAGATCTGGCCCTTATATGACGTGGCCATTTTAAACAGGAGAG
6	8B4	451	Sub-telomeric (chrom. 18)	CTCTGGAATTTGCATATTTTCAATACTCTGGCTCCAAATACTAGTCAGGAGGATCCTAGGCCAGCTGGGGAATTTATTTCTAAGGTTCTCTGAAG TAAACAATGTTAAACAGAGGTGAATTTTAGGAAGTAAAGGATGTGAAGTAGGAAGAGATGGACATAACTGAGGGGGGAATGATACCCATGGGAAC AGAGAAACCTCGGTGTGAGGTGTCAAGATGAGGAGACCCAGGGGCTCAAGTGAGCCCTCCGAGGGATGGCTGTCTGTCAGCAGAGATATGACTA GAGACAACCTCTCTGGGCCGACTGTCTAGAGAACAGCAGCGGCCACTGTTGGCTCTCACTGTGTGGCTGGGGAATAAAACGGCAGGAGGAGGGG ACAGGAAACCCAG
7	TBX5B1	332	Sub-telomeric (chrom. 12)	gcttcttgctcctcagAGCAGAAACCTTGGCGGGGCAAGGCCCCCTGGCGGCACCATGGCGAGCAGAGGGCTTTGGCCCTGGCGGCACAGGCCT CTGGAGCCTGACGCAAAAGACCTGCCCTGCGATTTCGAAACCCGAGAGCGGCTGGGGCCCCAGCAAGTCCCCGTCTCCCCGAGCCCGCTTC ACCCAGCAGGtaaggagacctcgcgcttcgggtccctttgcagagatcaaatcagagctctggtcttccctgctcggcttctctctg
8	10B4D	319	Sub-telomeric (chrom. 7)	CTTGCAACCTGAGTCTGAGTCGGCTGGGTGGGGCCCCCTGCACTGGAAGGAAGGCTGGCCCCCGACCCAGTGGTGGTTTTCAGGGCCTGTGTGAG GGTCACTTTTCAGGCTGTAGACCTGCAGCTCCCGAGGTGTGTCTCAGGCAAGTCCCTTGGCGGGCACAACCGGGAAGGTGTGTGAGGCGGC GTCTACCTGTGGCTTTAAACACTGGCTTCCACCTGCTGGCCCTCCGCGTCCCTCCAGCCCGGCGCTGGAG
9	TBX5Da	290	TBX gene (chrom. 12)	cctggtgctgaactgaagcacgcttcggtgcagtgcgctacctccagactctgagccagggcctctagtagcacctctcctcatctaggtctgtg ACGGGCAAGCTGAGCCCGCCATGCTGTGGCGCTGTGCTGACGTGCAACCCAGACTCCCCGCCACCGGGGGCATTGGATGAGGCAGCTCGTCTCCTT CCAGAAACTCAAGCTCACCAACCAACCTGAGCCCAATTTGGGC
10	5C3	282	Sub-telomeric (chrom. 8)	CTGTGTTCCAGTTTCGGACTGGGACCTGGAGCGGCGAGATGGGAACCTGTGCTCCCTGACCTTAAGAGCAGGAGGTCAAGAGCCCTGTGGGCT GAGTAATCCTCTGAAGCAGCTGTGGCTGGGCTGGAAGAAATGTGTTTTTCAGGCTTAATCTGTATTGATATGTATTCGGAATAATGTAATTTGTGTGT AAACAAGCAGCAGACTGGGCCAATTTCTGTGGCAG
11	4A4	235	Sub-telomeric (chrom. 4)	TCTCTGCGTCCCCCTCCCACTCAAGTTTCACTATGGCCAGATGTCCTCCGATGAAGAAGAGGAGGCCATGCGCAGAGCGTTCGAGGGGCGCA GGGTGGCCACACAGGCCAGGAGACCAACCTCTAACCTGTCTGACACAGGCTTAAGGGGAAGGTCTATGAAGAAGAACACAG

Table 1 (continued)

SEQ ID No.	Probe Name	Probe Size (bp)	Location	Sequence
12	A2Y	222	Y-linked probe (chrom.Y)	CTGTAACTCTAAGTATCAGTGTGAAACGGAGAGAAAACAGTAAAGGCAACGTCCAGGATAGAGTGAAGCGACCCATGAACGCATTTCATCGTGTGGTCTCGCGATCAGAGGCGCAAGATGGCT CTAGAGATCCCAAGATGCCAATACTCAGAGATCAGCAAGCAG
13	11G9	188	Sub-telomeric (chrom.19)	CTGCAGTGGGATGAGATGGGCTGAGGTTTGTGCCCTGTAGCCGTATGTGAACCATGGGGCAAGTGGTCAGCGGGGTCAGAGGTATTGTACAA GGGTCCACATAGGAATGGCAGGGTGTGAGCAG
14	TBX5A2	170	TBX gene (chrom.12)	tcaaagtcttcacctgagccctgctctccagcgaggcgactcctgcttttgcgctccaaagaagaggtgggatatgttgaggtaggttcacc ctggaggactgagggg
15	2D2	167	X-linked probe (chrom.X)	CCTCCCCTGCTCAGCACTCCTGGGATTGGAACTCTGTTCTCTCTGCAAGCCTCTAGCCCGTTCTCCAGCCCTCCCCAGACCAATCATGGG ATAGTCCGTAGG
16	D11	153	Non-human probe	CCACTAGGTGAACCATCACCCCTAATCAAGTTTTTTTGGGGTTCGAGGTCCCGTAAAGCACTAAATCGGAACCCCTAAAGGGAGCCCCCGATTTAGAG

**Table 2.** Oligonucleotides used for direct amplification of genomic DNA for generation of *MSH2* probes. MT, melting temperature; AT, annealing temperature; GCc, GC content; P1, promoter region 1 of *MSH2* gene; P2, promoter region 2 of *MSH2* gene.

Values for size and GC-content (%) indicated are of the amplified PCR products using a pair of forward (F) and reverse (R) primers.

SEQ ID No.	exon	Primers, 5'→3'	Size (bp)	MT (°C)	AT (°C)	GC (%)
17	P1F	AGTAACGGCCGCCAGTGTGCTGGTTTTCAATCTGTCGCCCAC	189	66	56	57
18	P1R	CGAGCGGCCGCCAGTGTGATGCCTGGGCAACATGGTAAAC	189	66	56	57
19	P2F	AGTAACGGCCGCCAGTGTGCTGCAATCTCCTGGGCTCAAGTG	218	68	58	45
20	P2R	CGAGCGGCCGCCAGTGTGATGACTGCCTTTATTCTGCTTAC	218	62	52	45
21	1F	AGTAACGGCCGCCAGTGTGCTGGCTTCGTGCGCTTCTTTTCAG	199	68	58	66
22	1R	CGAGCGGCCGCCAGTGTGATGCCGGCCCCATGTACTTGATC	199	70	60	66
23	2F	AGTAACGGCCGCCAGTGTGCTGAAGTCCAGCTAATACAGTGC	202	64	54	31
24	2R	CGAGCGGCCGCCAGTGTGATGCAACTCTATACTGACGAACC	202	64	64	31
25	3F	AGTAACGGCCGCCAGTGTGCTGGGTAACAATGATATGTCAGC	208	62	52	45
26	3R	CGAGCGGCCGCCAGTGTGATGGAGGAGAGCCTCAAGATTGG	208	68	58	45
27	4F	AGTAACGGCCGCCAGTGTGCTGATAGATAATTCAAAGAGGAG	199	58	48	38
28	4R	CGAGCGGCCGCCAGTGTGATGTGTACCTGATTCTCCATTTTC	199	62	52	38
29	5F	AGTAACGGCCGCCAGTGTGCTGTTAGGTTGCAGTTTCATCAC	193	62	52	38
30	5R	CGAGCGGCCGCCAGTGTGATGAAAAGGTTAAGGGCTCTGAC	193	64	54	38
31	6F	AGTAACGGCCGCCAGTGTGCTGGTTTTCTACTAATGAGCTTGC	221	62	52	39
32	6R	CGAGCGGCCGCCAGTGTGATGCTATTCTGTTCTTATCCATG	221	60	50	39
33	7F	AGTAACGGCCGCCAGTGTGCTGGTAGAAGATGCAGAATTGAG	208	62	60	39
34	7R	CGAGCGGCCGCCAGTGTGATGCAGAGCCTGTATAACATTAG	208	62	60	39
35	8F	AGTAACGGCCGCCAGTGTGCTGTTCTTTTAGGAAAACACCAG	228	60	50	31
36	8R	CGAGCGGCCGCCAGTGTGATGCTTTCTTAAAGTGGCCTTTG	228	62	52	31
37	9F	AGTAACGGCCGCCAGTGTGCTGCTTTGTTCTGTTTGCAGGTG	208	64	54	36
38	9R	CGAGCGGCCGCCAGTGTGATGCAACCTCCAATGACCCATTTC	208	66	56	36
39	10F	AGTAACGGCCGCCAGTGTGCTGTTGTTTATCAAGGCTTGGAC	196	62	52	35
40	10R	CGAGCGGCCGCCAGTGTGATGATTTAACACCATTTCTCTGG	196	60	52	35
41	11F	AGTAACGGCCGCCAGTGTGCTGCTGTTATTTTCGATTGTCAGC	195	62	52	29
42	11R	CGAGCGGCCGCCAGTGTGATGGACATTGAGAACATTATTAG	195	58	48	29

Table 2 (continued)

SEQ ID No.	exon	Primers, 5'→3'	Size (bp)	MT (°C)	AT (°C)	GC (%)
43	12F	AGTAACGGCCGCCAGTGTGCTGACTCAATGATGTGTTAGCTC	203	62	52	41
44	12R	CGAGCGGCCGCCAGTGTGATGTTTCATCTTGAACCTTCAACAC	203	60	50	41
45	13F	AGTAACGGCCGCCAGTGTGCTGTGCGACAACTGGGGTGATAG	192	66	56	49
46	13R	CGAGCGGCCGCCAGTGTGATGTTTCAGCCATGAACGTGGAG	192	66	56	49
47	14F	AGTAACGGCCGCCAGTGTGCTGGGAACCTTCTACCTACGATGG	207	66	56	40
48	14R	CGAGCGGCCGCCAGTGTGATGGTGGTGAGTGCTGTGACATG	207	68	58	40
49	15F	AGTAACGGCCGCCAGTGTGCTGTCTTATAGGTGTCTGTGATC	211	62	52	40
50	15R	CGAGCGGCCGCCAGTGTGATGCACTTCTTTGCTGCTGGTTC	211	66	56	40
51	16F	AGTAACGGCCGCCAGTGTGCTGCCAAGGTGAAACAAATGCCC	208	66	56	31
52	16R	CGAGCGGCCGCCAGTGTGATGACCTTCATTCATTACTGGG	208	64	54	31

Table 3. MSH2 exon probe sequences, gene ID, name and size

SEQ ID No.	Probe Name	Size	Exon	Sequence
53	P1	198	Promo ter	gttttcaatc tgtcgccac gctggagtc agtggcaca tttacggctg caccgcagcc tcgacctccc gggctcaggt gatccttttg cctcagccct gctaatactt gggatcacag acgtgggttt taccatgttg ccag
54	P2		Promo ter	caatctcttg ggtcgaagtg atccgcccac ctgggacctc caaattgctg ggattacagg cgtgagctac cgcgcccctgc cacaacgcga tatcttctaa cgtaccattt catttacttg ctatattcat tatctgaatt ttctcatatt agaattgaag cagaataaag gcagt
55	S1	338	1	gcgggaaaca gcttagtggg tgtggggctg cgcattttct tcaaccagga ggtgaggaag tttcgcacatg gcggtgcagc cgaaggagac gctgcagttg gagagcggcg ccgaggtcgg ctctcgtcgc ttctttcagg gcattgcggg gaagcccgacc accacagctgc gccttttcga cccggggcgc ttcttatcgg cgcacggcga ggacgcgctg ctggccgccc cggaggtgtt caagaccagc ggggtgatca agtacatggg gccggcagc
56	S2	220	2	ggagcaaaaga atctgcagag tgttctgctt agtaaatga attttgaatc ttttgtaaaa gatcttcttc tggttcgtca gtatagagtt gaagtttata agaatagac tggaaataag gcatacagga gaattgattgg taattggcat ataag
57	S3	332	3	cttggcaatc tctctcagtt tgaagatat tctctttgga acaatgatatt gtcagcttcc attggtgttg tgggtgttaa aatgtccgca gttagatggc agacacaggt tggagttggg tatgtggatt ccatacacag gaactagga ctgtgtgaat tccctgataa tgatcagttc aggcctcct catccagatt ggaccaaagg aatgtgtttt acccggagga gagactgctg gagacatggg gaaactgaga cag
58	S4	220	4	aaatagatna ttcaaaagagg aggaattctg atcacagaaa gaaaaaagc tgaactttcc acaaaagaca tttatcagga cctcaaccgg ttgttgaaag gcaaaaagg agagcagatg aatagtctg tatggccaga aatggagaat caggtacatg g
59	S5	209	5	gttgcagttt catcactgct tgcggtaatc aagtttttag aactcttattc agatgaattcc aactttggac agtttgaact gactactttt gacttcagcc agtatatga attgatatt gcagcagtcga gagcccttaa cctttttcag
60	S6	195	6	gggttctgtt gaagatacca ctggctctca gtctctgctg gccttgctga ataagtgtaa aacccctcaa ggacaaagac ttgttaacca gtggatttag cagcctctca tggataagaa cagaatagag gagag
61	S7	263	7	cagattgaat ttagtggag cttttgtaga agatgcagaa ttgaggcaga cttttacaaga agatttactt cgtcgattcc cagatcttaa cccgactgcc aagaagttc aaagacaaag agcaaacitaa caagattggt accgactcta tcagggtata aatcaactac ctaatgttata caggctctgg aaaaacatga agg

Table 3 (continued)

SEQ ID No.	Probe Name	Size	Exon	Sequence
62	S8	176	8	GGAACACACC AGAATATTATT GTTGGCAGTT TTTTGGACTC CTCCTTACTGA TCTTCGTCT GACTTCTCCA AGTTTCAGGA AATGATAGAA ACAACTTTAG ATATGGATCA Ggtatgc
63	S9	188	9	gcagGTGGA AACCATGAAT TCCTTGTAA ACCTTCAATT GATCCTAATC TCAGTGAATT AAGAGAATA ATGAATGACT TGGAAAGAA GATGCAGTCA ACATTAATAA GTGCAGCCAG AGAUCTTGG
64	S10	249	10	gttataaag GGCTTGGACC CTGGCAAAACA GATTAAACTG GATTCAGTG CACAGTTTGG ATATTACTTT CGTGTAACT GTAAAGGAAGA AAAAGTCCTT CGTAACAATA AAAACTTTAG TACTGTAGAT ATCCAGAAGA ATGGTGTAA ATTACCAAC AGgtttgcaa gtcgttatta tatttttaac c
65	S11	159	11	GAAGCCGAGG ATGCCATTGT TAAAGAAATT GTCAATATTT CTTCAGgtaa acttaataga actaatagt ttctgaatgt cacctggcctt ttggtaacag
66	S12	307	12	GGCTATGTAG AACCAATGCA GACACTCAAT GATGTGTTAG CTCAGTAGA TGCTGTGTC AGCTTTGCTC ACCTGTCAA TGGAGCACCT GTTCCATATG TAGGACCAGC CATTTTGGAG AAAGACAAG GAAGAATTAT ATTAAGCA TCCAGGCATG CTTGTGTTGA AGTTCAAGAT GAAATTGCAT TTATTCTTAA TGACGTATAC TTTGAAAAAG ATAAACAGAT GTTCCACATC ATTACTGg
67	S13	266	13	GGGCCCAATA TGGGAGGTAA ATCAACATAT ATTGACAAA CTGGGCTGAT AGTACTCATG GCGCAATTG GGTGTTTTGT GCCATGTGAG TCAGCAGAAG TGTCCATTGT GGAATGCAATC TTAGCCCGAG TAGGGGCTGG TGACAGTCAA TTGAAAGGAG TCTCCACGTT CATGGCTGAA ATGTTGGAAA CTGCTTCTAT CCTCAGg
68	S14	315	14	cagGTCTGCA ACCAAAGATT CATTAATAAT CATAGATGAA TTGGGAAGAG GAACTTCTAC CTACGATGGA TTTGGGTTAG CATGGGCTAT ATCAGATAC ATTGCAACAA AGATTGGTGC TTTTGTGATG TTTGCAACCC ATTTTCATGA ACTTACTGCC TTGGCCAATC AGATACCAAC TGTTAATAAT CTACATGTCA CAGCACTCAC CACTGAAGAG ACCTTAACTA TGCTTTATCA GGTGAAGAAA Ggtatg
69	S15	237	15	gGTGTCTGT ATCAAGTTT TGGGATTCAT GTTGCAGAGC TTGCTAATTT CCCTAAGCAT GTAATAGAT GTGCTAAACA GAAAGCCCTG GAACTTGAGG AGTTTCAGTA TATTGGAGAA TCGCAAGGAT ATGATATCAT GGAACCAGCA GCAAGAAGT GCTATCTGGA AAGAGAGg
70	S16	153	16	ctcatgggac attcacatgt gtttcagCAA GGTGAAAAAA TTATTCAGGA GTTCTGTGCC AAGGTGAAC AAATGCCCTT TACTGAATG TCAG

Table 4. *MLH1* exon probe sequences, gene ID, name and size

SEQ ID No.	Probe Name	Size	Exon	Sequence
71	L1	243	1	CTTCCGTTGA GCATCTAGAC GTTTCCTTGG CTCTTCCTGGC GCCAAATGT CGTTCGTGGC AGGGTTATT CGGCGGCTGG ACAGACAGT GGTGAACCGC ATCGCGCGG GGAAGTTAT CCAGCGGCA GCTAATGCTA TCAAGAGAT GATGAGAAC Tggtacggag ggagtggagc cggg
72	L2	276	2	ctcatattaa aatatgtaca ttagagtagt tgcagactga taaattattt tctgtttgat ttgccagTTT AGATGCAAAA TCCACAAGTA TTCAGTGTAT TGTAAAGAG GGAGGCTGA AGTTGATTC AATCCAAGAC AATGGCACCG GATCAGGgt aagtaaaacc tcaaagtagc aggatgtttg tgcgtttcat ggaagagtca ggacctttct c
73	L3	224	3	gagatttggg aaaatgagta acatgattat ttactcatct ttttggatct taacagAAAG AAGTCTGGA TATTGTATGT GAAAGTTCA CTACTAGTAA ACTGCAGTCC TTTGAGGATT TAGCCAGTAT TTCTACCTAT GGCTTTCGAG GTGAGgtaag ctgag
74	L4	171	4	cttttcttcc ttagcTTTG GCCAGCATAA GCCATGTGGC TCATGTTACT ATTACAACGA AACAGCTGA TGGAAAGTGT GCATACAGgt atagtgtga cttcttttac tc
75	L5	288	5	ttgatatgat tttctctttt ccccttggga ttagtatcta tctctctact ggataattaat ttgttatatt ttctcattag AGCAAGTTAC TCAGATGGAA AACTGAAAGC CCTCCTAAA CCATGTGCTG GCAATCAAGG GACCCAGATC A
76	L6	257	6	gggttttatt ttcaagtaact tctatgaatt tacaagaaaa atcaatcttc tgttcagTNG GAGGACCTTT TTTACAACAT AGCCACGAGG AGAAAAGCTT TAAAAATCC AAGTGAAGAA TATGGGAAA TTTTGGAAgt TGTTGGCAGg tacagtccaa aatctgggag tgggtctctg agatttgtca tcaaa
77	L7	167	7	ggctctgaca tctagtgtgt gtttttggca actcttttct tactcttttg tttttctttt ccaggtATTC AGTACACAAT GCAGGCATTA GTTTCTCAGT TAAAAAG
78	L8	149	8	CAAGGAGAGA CAGTAGCTGA TGTTAGGACA CTACCCAATG CCTCAACCGT GGACAATATT CGTCCGTCT TTGGAATGC TGTTAGTCGg
79	L9	184	9	GAGAACTGAT AGAAATGGA TGTGAGGATA AAACCTTAGC CTTCAAATG AATGGTTACA TATCCAATGC AAACACTCA GTGAAGAAGT GCATCTTCTT ACTCTTCATC AACGtaagt taaaa
80	L10	327	10	ttattgttta GATCGTCTGG TAGAATCAAC TTCCTTGAGA AAAGCCATAG AACAGTGTGA TGCAGCCTAT TTGCCAAAA ACACACACCC ATTCTGTATC CTCAGgtaat gtagcaccaa actctcctaac caagactcac aaggaacaga tgttctatca ggctctctc tttgaaagag atgagcatgc taatagtaca atcagagtga atccccataca ccaactggcaa aaggatgttc tgtccttct tacaggtaca aggcacag
81	L11	274	11	cccgacagTT TAGAATCAG TCCCAGAAAT GTGGATGTTA ATGTGCACCC CACAAAGCAT GAAGTTCAC TCCCTGCACGA GGAGAGCATC CTGGAGCGG TGCAGCAGCA CATCAGAGC AAGTCTCTGG GCTCCAATTC CTCAGGATG TACTTCACCC Aggtcagggc gcttctcctc cagctacttc tctctggggc ctttgaaatg tgccccg

Table 4 (continued)

SEQ ID No.	Probe Name	Size	Exon	Sequence
82	L12	359	12	CCTCTGGGGA GATGGTTAAAT CCACAACAAGT CTGACCTCGT CTCTACTTTC TGAAGTAGT GATAAGTCT ATGCCACCA GATGGTTCTGT ACAGATTCCC GGGAAACAGAA GCTTGATGCA TTCTGCAGC CTCTGAGCAA ACCCTGTCC AGTCAGCCCC AGGCCATTGT CACAGAGGAT AAGACAGATA TTCTAGTGG CAGGCTAGG CAGCAGATG AGGAGTGT TGAACCTCCA GCCCTGTCTG AAGTGGCTGC CAAAAATCAG AGCTTGGAG GGGATACAAC AAAGGGGA
83	L13	257	13	ccctttcttc attgcagaaa GAGACATCGG GAAGATTCTG ATGTGGAAT GGTGGAGAT GATTCCCGAA AGGAAATGAC TGCAGTTGT ACCCCCCGGA GAAGGATCAT TAACCTCACT AGTGTCTTGA GTCTCCAGGA AGAAATTAAT GAGCAGGGAC ATGAGGGTAC gtaaacgctg tggcctgctt gggatgcata 999
84	L14	205	14	gcagTTCTCC GGGAGATGTT GCATAACCAC TCCTTCGTGG GCTGTGTGAA TCCTCAGTGG GCCTTGGCAC AGCATCAAC CAAGTTATAC CTTCTCAACA CCACCAAGCT TAGataaatc agctgagtgt gtgtaacaag cagagct
85	L15	199	15	cagTGAAGAA CTGTTCTACC AGATACTCAT TTATGATTTT GCCAATTTTG GTGTTCTCAG GTTATCGgta agtttagatc ctttcaactt ctgacatttc aactgaccgc ccgcgaaca gtagctctcc actaaata
86	L16	303	16	cctagGAGCC AGCACCGCTC TTTGACCTTG CCATGCTTGC CTTAGATAGT CCAGAGAGTG GCTGGACAGA GGAAGATGGT CCCAAAGAAG GACTTGCTGA ATACATTGTT GAGTTTCTGA AGAAGAAGGC TGAGATGCTT GCAGACTATT TCCTTTTGA AATTGATGAG gtgtgacagc cattcttata cttctgttgt attctccaaa taaaatttcc agccgggtgc attggc
87	L17	311	17	gttcccttgt cctttttcct gcaagcagga AGGGAACCTG ATTGGATTAC CCTTCTGAT TGACAACTAT GTGCCCCCTT TGGAGGGACT GCCTATCTTC ATTCCTTCGAC TAGCCACTGA Ggtcagtgat caagcagata ctaagcattt cgtacatgc atgtgtgctg gagggaa
88	L18	229	18	gaggtattga atttcttttg accagTGAA TTGGGACGAA GAAAAGGAT GTTTTGAAG CCTCAGTAA GAATGCGCTA TGTCTATTTC CATCCGGAAG CAGTACATAT CTGAGGAGTC GACCCTCTAG GCCAGCAGgt acagtgggta tgacactggc accccaggac
89	L19	322	19	ccagAGTGA AGTGCCTGG CTCCATTCC AAACCTCTG GAAGTGGAC TGTGGAACA CATTGTCTA TAAAGCCTT GCGCTCACA CATTCTGCC TCCTAAACA TTTCACAGA AGATGGAAA TATCCTGCA GCTTGCTAA CCTGCCTGA TCTATACAA AGTCTTTGA GAGGTGTTA AATATGGTT ATTATGCA CTGTGGGAT GTGTTCTTC TTTCTCTGT ATTCCGATA CAAAGTGTT GTATCAAAAG TGTGATATA CAAAGTGA CC



Table 5. 60-mer Oligonucleotides of control, *MSH2* and *MLH1* for production of HNPCC microarrays

SEQ ID No.	Gene ID	Oligo Name	GC-content	Exon	Sequence
90	sub-telomeric	8D2-1	58%	Control	TGGCTTTTCTACTCCCGCAACCAGGAGCCTGACTAACAGGGGATGGCAGGCGACACATC
91	sub-telomeric	8B4-2	51%	Control	GAAATGATACCCATGGGAACAGAGAAAACCTGGTGTGAGGTGTGAGCATGAGGAGACCAAG
92	sub-telomeric	TBX5B1-3	56%	Control	CCAGCAGGTAAGGAGACCTCGCGCTTCGGGTCCCTTTGCAGAGATCAAAGTCAGAGTCTG
93	sub-telomeric	10B4D-4	61%	Control	CTGGTGAGGGTCACCTTTCAGGCTGCTTAGACCTGCAGCCTCCCCAGGTGGTGTGCTCAGG
94	TBX gene	TBX5Da-5	55%	Control	CTGGTGAGGGTCACCTTTCAGGCTGCTTAGACCTGCAGCCTCCCCAGGTGGTGTGCTCAGG
95	sub-telomeric	5C3-6	55%	Control	GACCTTAAGAGCAGGGAGGTGAGAGCCCTGTGGCTGAGTAATCCCTCTGAAGCATTGTC
96	sub-telomeric	4A4-7	55%	Control	CACAGGCCAGGAGACCAACCTCTAACCCCTGATCTGACACAGGTCTAAGGGGAAGGTCATG
97	Y-linked	A2Y-8	48%	Control	GAAAAACAGTAAAGGCAACGTCCAGGATAGAGTGAAGCGACCCATGAACGCATTTCATCGTG
98	sub-telomeric	11G9-9	56%	Control	GTAGCGTATGTGAACCATGGGGCAAGGTGGTGCAGCGGGGGTCAAGAGGTATTGTACAAGG
99	TBX gene	TBX5A2-10	53%	Control	CACCTCTGGCTTTTGGCTCCAAAGAAGAGGTGGGATAGTTGGAGGTGAGTTTCACCCCTG
100	X-linked	2D2-11	56%	Control	CTCAGCACTCCTGGGATTTGGAACCTCGTTCCCTCTCTGCAAGCCTCCTAGCCCCGGTTCT
101	Non-human	D11-12	46%	Control	CTAATCAAGTTTTTTTGGGTCGAGGTGCCGTAAAGCACATAAATCGGAACCCCTAAAGGGAG
102	<i>MSH2</i>	<i>MSH2</i> -p1	58%	Promoter	GTTTTCAATCTGTGCCCCCAGCTGGAGTGCAGTGGCACAATTTACGGCTG CACCGCAGCC
103	<i>MSH2</i>	<i>MSH2</i> -p2	51%	Promoter	CAAAATGCTGGGATTACAGGCGTGAGCTACCGGCCCTGCCACAACGCATATCTTCTAA
104	<i>MSH2</i>	<i>MSH2</i> -1	60%	1	CTTCGTGCGCTTCTTTTCAGGGCATGCCGGAGAAGCCGACCACCACAGTGGCCTTTTCGA
105	<i>MSH2</i>	<i>MSH2</i> -2	31%	2	CTGCAGAGTGTGTGCTTAGTAAATGAATTTTGAATCTTTTGTAAAGATCTTCTTCTG

Table 5 (continued)

SEQ ID No.	Gene ID	Oligo Name	GC-content	Exon	Sequence
106	MSH2	MSH2-3	46%	3	GACAGGTTGGAGTTGGGTATGTGGATTCCATACAGAGGAAACTAGGACTGTGTGAATTCC
107	MSH2	MSH2-4	48%	4	GGACCTCAACCGGTTGTTGAAAGGCCAAAGGGAGAGCAGATGAATAGTGTGTATTGGCC
108	MSH2	MSH2-5	41%	5	GAACTGACTACTTTTTGACITTCAGCCAGTATATGAATAATTGGATATTGCAGCAGTCAGAGCC
109	MSH2	MSH2-6	48%	6	CTGTTGAAGATACCACCTGGCTCTCAGTCTCTGGCTGCTTGTGCTGAATAAGTGTAAACCC
110	MSH2	MSH2-7	45%	7	CTTCGTCGATCCCGATCTTAACCGACTTGGCCAGAAGTTTCAAAGACACAGCAGCAAAC
111	MSH2	MSH2-8	41%	8	GCAGTTTTTTTGTAACCTCTTACTGATCTTCGTTCTGACTTCTCCAAGTTTCAGGAAATG
112	MSH2	MSH2-9	35%	9	GGTGGAAAACCATGAATTCTTTGTAAACCTTCATTGTGATCCTAATCTCAGTGAATTAAG
113	MSH2	MSH2-10	43%	10	GCTTGGACCCCTGGCAAAACAGATTAAACTGGATTCCAGTGCACAGTTTGGATATTACTTTC
114	MSH2	MSH2-11	33%	11	GACTTCTTTAAATGAAGAGTATACCAAAAATAAAAACAGAAATATGAAGAGCCAGGATGC
115	MSH2	MSH2-12	48%	12	CTCAGCTAGATGCTGTGTGTGTCAGCTTTGCTCACGTGTCAAATGGAGCACCTGTTCCATATG
116	MSH2	MSH2-13	51%	13	GGTGTGTTTGTGCCATGTGAGTCAGCAGAAAGTGTCCATTGTGGACTGCATCTTAGCCCCGAG
117	MSH2	MSH2-14	41%	14	GAACTTACTGCCTTGGCCAATCAGATACCAACTGTTAATAATCTACATGTCACAGCACTC
118	MSH2	MSH2-15	41%	15	GGGATTCATGTTGCAGAGCTTGCTAATTTCCCTAAGCATGTAATAGAGTGTGCTAAACAG
119	MSH2	MSH2-16	33%	16	GCCCTTTTACTGAAATGTGAGAAGAAACATCAATAAAGTTAAACACAGCTAAAGCTGA
120	MLH1	MLH1-1	56%	1	CAAAATGTCGTTTCGTGGCAGGGGTTATTTCGGCGGCTGGACGAGACAGTGGTGAACCGCAT
121	MLH1	MLH1-2	41%	2	CAAGTGATTTGTTAAAGAGGGAGGCCCTGAAGTTGATTTCAGATCCCAAGACAATGGCACCCGGG

Table 5 (continued)

SEQ ID No.	Gene ID	Oligo Name	GC%	Exon	Sequence
122	MLH1	MLH1-3	41%	3	GGTTCAC TACTAGTAAACTGCAGTCCCTTTGAGGATTTAGCCAGTATTTCTACCTATGGCT
123	MLH1	MLH1-4	45%	4	GGCCAGCATAAGCCATGTGGCTCATGTTACTATTACAACGAAAAACAGCTGATGGAAAGTG
124	MLH1	MLH1-5	48%	5	GCAAGTTACTCAGATGGAATACTGAAAGCCCTCCTAAACCATGTGTGGCAATCAAGGG
125	MLH1	MLH1-6	38%	6	GGAGGACCTTTTTCACATAGCCACGAGGAGAAAAGCTTTAAAAAATCCAAGTGAAGA
126	MLH1	MLH1-7	35%	7	CTCTTTTGTCTTTTCCAGGTAATTCAGTACACAATGCAGGCATTAGTTTCTCAGTTA
127	MLH1	MLH1-8	50%	8	GACAGTAGCTGATGTTAGGACACTACCCCAATGCCCTCAACCGTGGACAATATTGGCTCCGT
128	MLH1	MLH1-9	40%	9	CCCTAGCCTTCAAAAATGAATGGTTACATATCCAATGCAAACTACTCAGTGAAGAAGTGCA
129	MLH1	MLH1-10	46%	10	GCCATAGAAACAGTGTATGACGCCCTATTTGGCCAAAAAACACACACCCATTCTGTACCTC
130	MLH1	MLH1-11	56%	11	CAAAGCATGAAGTTCACCTTCCCTGACGAGGAGAGCATCTCTGGAGCGGGTGCAGCAGCACA
131	MLH1	MLH1-12	51%	12	GGTTCGTACAGATTCCCGGGAACAGAAAGCTTGATGTCATTTCTGCAGCCTCTGAGCAAACC
132	MLH1	MLH1-13	45%	13	CATCGGGAAGATTCTGATGTGGAATAATGGTGAAGATGATTCGCCAAAGGAATGACTGCA
133	MLH1	MLH1-14	55%	14	GCATAACCACTCCTTCGTGGGCTGTGTGAATCCTCAGTGGGCCCTTGGCACAGCATCAAAC
134	MLH1	MLH1-15	36%	15	GAACTGTTCTACCAGATACCTCATTTATGATTTTGCCAAATTTTGGTGTCTCAGGTTATCG
135	MLH1	MLH1-16	55%	16	GACCTTGCCATGCTTGCCCTTAGATAGTCCAGAGAGTGGCTGGACAGAGGAAGATGGTCCC
136	MLH1	MLH1-17	51%	17	GGGAACCTGATTTGGATTACCCCTTCTGATTTGACAACTATGTGCCCTTTTGGAGGGACTG
137	MLH1	MLH1-18	45%	18	CCTCAGTAAAGAATGCGCTATGTTCTATTCCATCCGGGAAGCAGTACATATCTGAGGAGTC
138	MLH1	MLH1-19	50%	19	CTCCTGGAAAGTGGACTGTGGAAACACATTTGTCTATAAAGCCTTGGGCTCACACATTTCTGCC

**Claims**

1. Method for hybridisation of probes onto immobilized genomic DNA comprising the steps of:
  - (a) providing genomic DNA and denaturing said genomic DNA;
  - (b) immobilizing said denatured genomic DNA onto a matrix;
  - (c) providing a set of probes and passing said probes through said matrix under conditions favouring hybridisation of the probes to its complementary sequence in said genomic DNA; and
  - (d) washing off non-hybridised probes through said matrix, leaving formed hybridised genomic DNA/probe complexes for further analysis.
2. Method according to claim 1, wherein said genomic DNA is undigested genomic DNA.
3. Method according to any of claims 1 or 2, wherein said genomic DNA is isolated.
4. Method according to any of claims 1 to 3, wherein said denatured genomic DNA is permeated within said matrix.
5. Method according to any of claims 1 to 4, wherein said probes are passed through said matrix by at least one cycle of alternating downwards and upwards flow.
6. Method according to any of claims 1 to 5, wherein said washing step is carried out by passing through said matrix a wash fluid by at least one cycle of downwards flow.
7. Method according to any of claims 1 to 6, wherein said matrix is a membrane.
8. Method according to claim 7, wherein said membrane comprises a 3D network structure.
9. Method according to claim 8, wherein said network structure is a flow-through structure.
10. Method according to claim 8 or 9, wherein said network structure is a fibre network structure.

11. Method according to claim 10, wherein said fibre is of vegetable origin.
12. Method according to claim 11, wherein said fibre is cellulose.
13. Method according to any of claims 1 to 12, wherein the matrix allows for a flow rate comprised between 50mm/30min and 250mm/30min including the outer limits.
14. Method according to any of claims 1 to 13, wherein said matrix is activated with an affinity conjugate.
15. Method according to claim 14, wherein said affinity conjugate is chosen from the group comprising poly-L-lysine, poly-D-lysine, 3-aminopropyl-triethoxysilane, poly-arginine, polyethyleneimine, polyvinylamine, polyallylamine, tetraethylenepentamine, ethylenediamine, diethylenetriamine, triethylenetetramine, pentaethylenehexamine and hexamethylenediamine.
16. Method according to claim 15, wherein said affinity conjugate is poly-L-lysine.
17. Method according to any of claims 1 to 16, wherein said probes are flanked by primer binding sequences.
18. Use of a method according to any of claims 1 to 17 for genomic DNA hybridisation.
19. Use of a method according to any of claims 1 to 17 for detection and quantification of target nucleic acids in a genomic DNA sample.
20. Method for target nucleic acid detection and quantification in a genomic DNA sample comprising the steps of:
  - (a) providing genomic DNA and denaturing said genomic DNA;
  - (b) performing a hybridisation according to a method as described in any of claims 1 to 17;
  - (c) recovering hybridised probes; and essentially simultaneously amplifying any recovered probe using a single primer pair, each member of said primer

pair binding to each recovered probe onto the respective flanking primer binding sequences of said probe; and,

(d) qualitatively and quantitatively analysing the recovered amplified probes of step (c).

21. Method according to claim 20, wherein the analysis of step (d) is by microarray analysis.
22. Method according to claim 20 or 21, wherein each probe is flanked 5' and 3' by primer binding regions with said 5' and 3' flanking primer binding sequences being the same or substantially the same for each probe.
23. Method according to any of claims 20 to 22, wherein said amplification of step (c) is a quantitative amplification.
24. Method according to claim 23, wherein said amplification is by means of polymerase chain reaction.
25. Method according to any of claims 20 to 24, wherein the amplified probes are provided with a label.
26. Method according to claim 25, wherein said label is a fluorescent label.
27. Use of a method according to any of claims 20 to 26 for genomic screening.
28. Use of a method according to any of claims 20 to 26 for detecting deletions or duplications in genomic DNA.
29. Use of a method according to any of claims 20 to 26 for genome profiling.
30. Use of a method according to any of claims 20 to 26 for identifying and quantitatively detecting the degree of pathogenesis, disease or contamination in a sample.
31. Use of a method according to any of claims 20 to 26, for identifying and detecting the presence of infectious agents in a sample.

32. Use of a method according to any of claims 20 to 26, for genotyping pathogens present in a sample.
33. Device for flow-through hybridisation of probes onto immobilized genomic DNA comprising a well holder, said well holder comprising one or more round wells with a fixed diameter, said wells exposing a fibre network matrix; wherein said matrix permits immobilization of undigested genomic DNA and which allows hybridisation of said immobilized genomic material with probes by flow-through hybridisation.
34. Device according to claim 32, wherein said matrix permits permeation of undigested genomic DNA.
35. Apparatus for flow-through hybridisation of probes onto immobilized genomic DNA comprising:
- (a) a device according to claim 33 or 34;
  - (b) means for addition of a controlled amount of fluid to at least one of the wells of the device as described in (a);
  - (c) means for applying and/or maintaining a controlled pressure difference over the matrix in each of the wells.
36. Kit for flow-through hybridisation of probes onto immobilized genomic DNA comprising :
- (a) a device according to claim 33 or 34; and
  - (b) instructions to carry out a method according to any of claims 1 to 26.
37. Kit according to claim 36, additionally comprising:
- (a) a set of probes, wherein each probe is flanked 5' and 3' by primer binding regions with said 5' and 3' flanking primer binding sequences being the same or substantially the same for each probe;
  - (b) a single primer pair, each member of said pair being complementary to a primer binding region;
  - (c) optionally amplification components allowing the amplification of any recovered hybridised probe; and
  - (d) optionally a microarray, said microarray allowing analysis of the hybridisation results obtained by a method according to any of claims 1 to 26.

**Abstract**

The present invention is directed to a novel method of efficiently hybridising probes onto immobilized genomic DNA and/or RNA comprising the steps of (a) providing genomic DNA and denaturing said genomic DNA; (b) immobilizing said denatured genomic DNA onto a matrix; (c) providing a set of probes and passing said probes through said matrix under conditions favouring hybridisation of the probes to its complementary sequence in said genomic DNA; and (d) washing off non-hybridised probes through said matrix, leaving formed hybridised genomic DNA/probe complexes for further analysis.

The present invention is further directed to a novel method for target nucleic acid detection and quantification in a genomic DNA sample comprising the steps of: (a) providing genomic DNA and denaturing said genomic DNA; (b) performing a hybridisation according to a method as described above; (c) recovering hybridised probes; and essentially simultaneously amplifying any recovered probe using a single primer pair, each member of said primer pair binding to each recovered probe onto the respective flanking primer attachment sequences of said probe, and (d) qualitatively and quantitatively analysing the recovered amplified probes of step (c).

The present invention also relates to the uses thereof as well as devices, apparatus and kits for performing said methods of the invention.



1/6




FIGURE 1





FIGURE 2

A



B




FIGURE 3




FIGURE 4





FIGURE 5



**FIGURE 6**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**